Phosphatidylethanolamine N-methylation was examined in cardiac subcellular membranes after inducing chronic experimental diabetes in rats (65 mg streptozotocin/kg, i.v.). The incorporation of radiolabeled methyl groups from S-adenosyl-L-methionine in diabetic sarcolemma was significantly depressed at all three catalytic sites (I, II, and III) of the methyltransferase system. An increase in methyl group incorporation was evident at site I without any changes at sites II and III in diabetic sarcoplasmic reticulum and mitochondria. Similar changes were also seen for the individual N-methylated lipids (monomethyl-, dimethylphosphatidylethanolamine, and phosphatidylcholine) specifically formed at each catalytic site in all cardiac membranes from diabetic animals. These alterations in N-methylation were reversible by a 14-d insulin therapy to the diabetic animals. In the presence of 10 MM ATP and 0.1 gM ca2+, N-methylation was maximally activated at site I in both control and diabetic sarcolemma and sarcoplasmic reticulum, but not in mitochondria. Incubation of cardiac membranes with of S-adenosyl-L-methionine showed that Ca2+-stimulated ATPase activities in both sarcolemma and sarcoplasmic reticulum were augmented; however, the activation of diabetic sarcolemma was lesser and that of diabetic sarcoplasmic reticulum was greater in comparison with the control preparations. These results identify alterations in phosphatidylethanolamine N-methylation in subcellular membranes from diabetic heart, and it is suggested that these defects may be crucial in the development of cardiac dysfunction in chronic diabetes. (J.
Introduction
Phospholipid N-methylation reaction consists of the sequential addition of three methyl groups from the physiological donor S-adenosyl-L-methionine (AdoMet)' to the amino moiety of an intramembranal phosphatidylethanolamine (PE) molecule (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) . The final synthesis of phosphatidylcholine (PC) is preceded by the formation of intermediates, phosphatidyl-N-monomethylethanolamine (PMME) and phosphatidyl-N,N-dimethylethanolamine (PDME), in the presence of the membrane-bound methyltransferase system. Previous studies in our laboratory using rat heart subcellular membranes have shown the existence of three methyltransferase catalytic sites (I, II, and III) for PE N-methylation, each exhibiting different kinetic parameters, pH profile, sensitivity to divalent cations, and pathobiological behavior (1, 2, 7, 9) . These three sites can be identified at 0.055 uM (site I), 10 AM (site II), and 150 uM (site III) concentrations of AdoMet (1, 2, 7) . Under optimal conditions, predominant synthesis of specific N-methylated phospholipids, namely PMME, PDME, and PC, was found to occur in cardiac membranes at sites I, II, and III, respectively (2, 7) .
The phospholipid N-methylation has been suggested to be important in changing several membrane associated functions (3) including the control of Ca2+ fluxes in the myocardium (4) (5) (6) . Furthermore, a defect in PE N-methylation has been demonstrated in cardiac hypertrophy (7) , alcoholic cardiomyopathy (8) , and catecholamine-induced cardiomyopathy (9) . Although alterations in PE N-methylation have also been shown in cardiac sarcolemma (heavy fraction) obtained from diabetic rats (10) , no information concerning changes in PE N-methylation activity in cardiac sarcoplasmic reticulum (SR) and mitochondria due to this disease is available in the literature. The present study, therefore, was undertaken to investigate the PE N-methylation activity in SR and mitochondria from animals with streptozotocin-induced diabetes; sarcolemmal (SL) membrane (light fraction) was used for the purpose of comparison. In addition, this study examined whether changes in PE N-methylation activity in different subcellular membranes were reversible upon treatment ofdiabetic animals with insulin. It may be pointed out that chronic diabetes due to streptozotocin has been shown to result in a cardiomyopathy associated with defects in cardiac ultrastructure, function, and metabolism (10) (11) (12) (13) (14) . Because PE N-methylation has been shown to increase the Ca2"-pump activities in heart SL and SR (4, 5) , the effects of PE N-methylation on the SL and SR Ca2"-stimulated ATPase activities in control and diabetic hearts were also studied. Methods before they were killed at 8 wk. Hearts were removed, atria and any large vessels were carefully trimmed, and the ventricular tissue was processed for the isolation of subcellular membranes. Blood samples were taken at the time of sacrifice and analyzed for plasma insulin concentration by standard radioimmunoassay technique (Amersham Corp., Arlington Heights, IL) and for glucose levels by means of a glucose reagent kit (Sigma Chemical Co., St. Louis, MO). The above experimental protocol is similar to that employed elsewhere for establishing the presence of diabetic cardiomyopathy (10) (11) (12) (13) (14) .
Preparation of cardiac subcellular membranes. Purified light sarcolemmal preparation was isolated from pools of two to three hearts according to the method described by Pitts (15) . Membrane fraction enriched with sarcoplasmic reticulum (microsomal fraction) was isolated according to the method of Harigaya and Schwartz (16) as described elsewhere (14) . The mitochondrial fraction was isolated by the method of Sordahl et al. (17) . All these procedures were carried out at 0-50C, and the membrane activities were assayed immediately after completion of the isolation protocol. To determine the purity of membranes, the activities of marker enzymes such as ouabain-sensitive Na',K+-ATPase (12) , cytochrome c oxidase (14) , rotenone-insensitive NADPH cytochrome c reductase, and K+-EDTA ATPase (14) were measured in all the membrane preparations.
PE N-methylation assay. Phospholipid methyltransferase activity was assayed by measuring the incorporation of [3H]methyl groups into membrane phospholipids in the presence of S-adenosyl-L-[methyl-
-3H]methionine ([3HJAdoMet) as described earlier (1, 2) . Assays were performed with 0.5 mg of membrane protein in 0.5 ml of reaction medium under optimal conditions for the three catalytic sites involved in the methyltransferase reactions, as indicated previously (1, 2 was terminated 30 min later with the addition of 3 ml of chloroform/ methanol/2 N HCl (6:3:1, by volume), followed by washing three times with 2 ml of 0.1 M KC1 in 50% methanol. In addition to the measurement oftotal methyl group incorporation, the N-methylated phospholipids (PMME, PDME, and PC) were separated by thin-layer chromatography and the methyl group incorporation in these lipid products was determined (1, 2 (20) .
Results
The experimental animals showed, 8 wk after the injection of streptozotocin, elevated levels ofplasma glucose and decreased levels of plasma insulin. These diabetic animals exhibited depressed body weight and heart weight in relation to control animals but showed a higher heart weight/body weight ratio (Table I ). Such characteristics of the diabetic animals are similar to those reported earlier (10) (11) (12) (13) (14) . Insulin-treated diabetic rats showed normalized plasma glucose, insulin levels, and other parameters except that the body weight was still decreased in this group. The protein yields for SL, SR, and mitochondria from experimental hearts were similar to those for the control preparations (Table I) . Subcellular membranes prepared from the hearts were examined (n = 4) for the marker enzyme activities in order to determine the possible extent of cross contamination. The SL vesicles prepared by discontinuous sucrose density gradient (15) In a previous study (10) , using heavy SL membranes prepared by the hypotonic shock/LiBr treatment method, we have reported a depressed PE N-methylation activity at all three sites in diabetic hearts. To test whether the changes in methylation activities shown earlier were not due to any artifacts associated with the method of SL preparation, PE Nmethylation was carried out in light SL prepared by the sucrose-density gradient method (15) . The data in Table II indicate that all three catalytic sites were depressed in diabetic preparation and thus, the present results confirm our earlier findings. Furthermore, treatment of diabetic animals with insulin was found to normalize the observed changes in the SL PE N-methylation activities (Table II) . Since the weight loss occuring in diabetes (10) may be responsible for changes in phospholipid N-methylation, weight-matched control rats (Figs. 1 and 2 ). The activity curves for the three sites, studied under optimal conditions in SR and mitochondria, indicate that the methylation activity for site I, unlike sites II and III, was increased in diabetic heart. Since catalytic site I in heart SR and mitochondria was sensitive to the diabetic condition, PE N-methylation activity in these preparations was studied in the presence of different concentrations of [3H]AdoMet (0.022-0.22 ,uM) and the results are presented in Fig. 3 . At all the concentrations of AdoMet employed both diabetic SR and mitochondrial membranes had significantly higher activity of PE N-methylation than control preparations. Treatment of the diabetic animals with insulin for 2 wk reversed the changes towards the control values. The weight-matched as well as weight-and agematched control animals showed normal activities (Table III) . 4 . 2. Fig. 1 and results are mean±SE of four experiments. *Significantly (P < 0.05) different from control. Table IV shows the formation of N-methylated phospholipids at site I PE N-methylation in SL, SR, and mitochondria from control and diabetic hearts. It should be noted that PMME was the major lipid intermediate whereas PDME and PC were formed in lesser quantities in all the membranes studied. In comparison with the respective control membranes, the formation of these lipid products was significantly lower in diabetic SL, but it was higher in diabetic SR and mitochondria. From Table IV it is also apparent that SR and mitochondrial activation of the first methyltransferase step, which is rate-limiting (23) , results in an increased intramembranal availability of methylated precursors for the second and consequently the third step, with an overall increased synthesis of all the three methylated lipids under these assay conditions. Treatment of diabetic animals with insulin for a period of 2 wk was found to normalize the diabetes-induced changes in these phospholipid intermediates (data not shown) as has been reported for skeletal muscle microsomes (24) . On the other hand, under conditions typical for assaying catalytic sites II and III, no difference in the N-methylated products (PMME, PDME, and PC) was found between control and diabetic mitochondrial as well as SR preparations. The values (n = 3) for PMME, PDME, and PC were reduced by 34±3%, 39±2%, and 33±4% in diabetic SL at site II and by 38±3%, 32±4%, and 44±4% at site III, respectively, but were normalized by the 2-wk insulin treatment.
Physiological concentrations of Ca2+ in the presence of micromolar ATP are known to stimulate PE N-methylation in the liver (25) and skeletal muscle microsomes (24) . It has been shown that PE methyl transfer reaction starts on the cytoplasmic side of the membranes where cytosolic AdoMet is available to donate methyl groups (3) . Therefore, in the beating heart cell, phospholipid methylation can be seen to occur in the presence of cytosolic levels of free Ca2" ranging from -lO-' M during rest to lO-' M in response to excitation (26) . (l0-7 to l0-4 M) plus 10 ,gM ATP on the PE N-methylation activity at 0.055 ,uM AdoMet (site I, where PMME is specifically synthesized) in cardiac SL, SR, and mitochondria from control and diabetic hearts. The addition of Ca2" stimulated SL and SR methylation in both control and diabetic preparations; the activation was maximal at l0-7 M Ca2' and then declined toward basal values at higher Ca2+ concentrations. On the other hand, in both control and diabetic mitochondria, a significant (P < 0.05) inhibition of PE N-methylation was observed at l0-4 M Ca2+. It may be noted that at each Ca2+ Table II. concentration, the diabetic hearts exhibited lower methylation activity in SL but higher activities in both SR and mitochondria (Fig. 4) . The SL, SR, and mitochondrial membranes obtained from insulin-treated diabetic hearts showed site I methyltransferase activities comparable to those ofcontrol hearts in concentrations, respectively. As reported in previous studies (14, 19) , the basal activities of both SL and SR Ca2+ pumps were found to be markedly depressed in diabetes (Table V) . The effects of incubation of cardiac SL and SR in the presence of AdoMet on Ca2_-stimulated ATPase are also shown in Table V . Membranes obtained from control and diabetic hearts were preincubated for 5 min at 370C with varying concentrations of AdoMet (0.1, 10, and 150 uM) as a methyl donor for the intramembranal synthesis of N-methylated phospholipids by the methyltransferase system (4, 5) . Under these conditions, stimulation ofboth SL and SR Ca2' pumps has been shown to occur at 10 and 150 ,M AdoMet concentrations which are known to induce a predominant synthesis and intramembranal accumulation of PDME and PC, respectively (4, 5) . At 10 MM AdoMet, Ca2+-stimu- (Table V) . The Ca2+-stimulated ATPase activity in the SR preparations was also increased by incubation with AdoMet; however, owing to its higher methyltransferase activity, the diabetic membrane exhibited a higher AdoMet-dependent stimulation of the Ca2+ pump in comparison to control preparations (Table V) . In particular, upon methylating the diabetic SR membrane with 10 or 150 AM AdoMet the depressed Ca2+ pump activity became higher or equal, respectively, in comparison to the basal Ca 2 pump activity in control membranes. It may be noted also that the Ca>2 pump in control SR was maximally stimulated at 150 AM AdoMet (high intramembranal levels of PC), whereas maximal stimulation occurred at 10 MM AdoMet (high intramembranal PDME) in diabetic SR. This finding may suggest that, unlike the control SR membranes, PDME molecules in diabetic SR may be of greater functional significance. The Mg2+ ATPase activity of the cardiac subcellular membranes was not affected by diabetes (Table VI) . In this regard, the values (n = 3-4) for control preparations were 
Discussion
The results of this study indicate that the rate-limiting step of the methylation pathway (catalytic site I) was increased in the 8-wk diabetic SR and mitochondria. In contrast, previous studies (10) have reported a decrease of all three sites in heavy sarcolemma from the 8-wk diabetic hearts, which finding is confirmed by using the light SL preparation in this study. It is unlikely that these changes in PE N-methylation were due to differential contamination in the subcellular fractions because the marker enzyme activities in SL, SR, and mitochondria showed equal but negligible cross-contamination in both control and experimental preparations. In fact the increase of PE N-methylation in diabetic mitochondria and SR at site I was Cardiac Phospholipid Methylation in Diabetes 781 specific in nature because sites II and III in these fractions were unaltered. Since streptozotocin-induced diabetes in rats is associated with loss of body weight, it can be argued that the observed changes in cardiac phospholipid methylation are due to the catabolic effect of diabetes. Because our experiments with weight-matched as well as weight-and age-matched control animals showed values for the phospholipid methylation (26) . The Ca2+ plus ATP-induced effect on phospholipid methylation was also seen in liver and skeletal muscle microsomes, where it was suggested to be mediated by a calmodulin-dependent regulatory system (24, 25) . Whether or not calmodulin intrinsic to the heart SL and SR membranes is essential in conferring Ca2" sensitivity to the N-methyltransferase system remains to be elucidated in future studies. However, the maximal activation with micromolar ATP seems to suggest the involvement of a phosphorylation mechanism.
